170 related articles for article (PubMed ID: 36857932)
1. Recent advances of LSD1/KDM1A inhibitors for disease therapy.
Zhang C; Wang Z; Shi Y; Yu B; Song Y
Bioorg Chem; 2023 May; 134():106443. PubMed ID: 36857932
[TBL] [Abstract][Full Text] [Related]
2. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.
Shen L; Wang B; Wang SP; Ji SK; Fu MJ; Wang SW; Hou WQ; Dai XJ; Liu HM
J Med Chem; 2024 Jan; 67(2):922-951. PubMed ID: 38214982
[TBL] [Abstract][Full Text] [Related]
4. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
Fang Y; Liao G; Yu B
J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
[TBL] [Abstract][Full Text] [Related]
5. Lysine-Specific Demethylase 1 (LSD1) Inhibitors: Peptides as an Emerging Class of Therapeutics.
Baby S; Shinde SD; Kulkarni N; Sahu B
ACS Chem Biol; 2023 Oct; 18(10):2144-2155. PubMed ID: 37812385
[TBL] [Abstract][Full Text] [Related]
6. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.
Song Y; Zhang H; Yang X; Shi Y; Yu B
Eur J Med Chem; 2022 Jan; 228():114042. PubMed ID: 34915312
[TBL] [Abstract][Full Text] [Related]
7. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
[TBL] [Abstract][Full Text] [Related]
8. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
[TBL] [Abstract][Full Text] [Related]
9. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials.
Noce B; Di Bello E; Fioravanti R; Mai A
Front Pharmacol; 2023; 14():1120911. PubMed ID: 36817147
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and structure-activity relationship of TAK-418 and its derivatives as a novel series of LSD1 inhibitors with lowered risk of hematological side effects.
Hattori Y; Matsumoto S; Morimoto S; Daini M; Toyofuku M; Matsuda S; Baba R; Murakami K; Iwatani M; Oki H; Iwasaki S; Matsumiya K; Tominari Y; Kimura H; Ito M
Eur J Med Chem; 2022 Sep; 239():114522. PubMed ID: 35749987
[TBL] [Abstract][Full Text] [Related]
11. An Update of Lysine Specific Demethylase 1 Inhibitor: A Patent Review (2016-2020).
Zheng YC; Liu YJ; Gao Y; Wang B; Liu HM
Recent Pat Anticancer Drug Discov; 2022; 17(1):9-25. PubMed ID: 34323202
[TBL] [Abstract][Full Text] [Related]
12. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
13. Annual review of LSD1/KDM1A inhibitors in 2020.
Fu DJ; Li J; Yu B
Eur J Med Chem; 2021 Mar; 214():113254. PubMed ID: 33581557
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
16. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
[TBL] [Abstract][Full Text] [Related]
17. Advances toward LSD1 inhibitors for cancer therapy.
Fu X; Zhang P; Yu B
Future Med Chem; 2017 Jul; 9(11):1227-1242. PubMed ID: 28722477
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia.
Teresa Borrello M; Benelkebir H; Lee A; Hin Tam C; Shafat M; Rushworth SA; Bowles KM; Douglas L; Duriez PJ; Bailey S; Crabb SJ; Packham G; Ganesan A
ChemMedChem; 2021 Apr; 16(8):1316-1324. PubMed ID: 33533576
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
Ma QS; Zhang YF; Li CY; Zhang WX; Yuan L; Niu JB; Song J; Zhang SY; Liu HM
Eur J Med Chem; 2023 May; 251():115228. PubMed ID: 36881982
[TBL] [Abstract][Full Text] [Related]
20. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
